Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01575548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT01575548 · ClinicalTrials.gov record · last posted 2026-08-10

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

StatusActive, Not Recruiting
PhasePhase 3
Started2012-08-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Amendment record 843 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 843 times since 2012-04-10; most recent amendment 2026-06-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2017-07-26
Status change Recruiting→Active, Not Recruitingv583
2013-01-14
Status change Not Yet Recruiting→Recruitingv15
2012-11-29
Status change Recruiting→Not Yet Recruitingv14
2012-09-16
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT01575548
Lead Sponsor National Cancer Institute (NCI)
Conditions Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Enrollment 129 participants
Start Date 2012-08-08
Primary Completion 2018-07-17 (estimated)
Study Completion 2027-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-10